hoodb.com

藥華藥(6446)T細胞受體免疫療法TCRT-ESO-A2-TW用於治療末期實體 腫瘤患者之第一期臨床試驗申請案(IND)進度更新(1/2日股價602元)

|

You are leaving and open the following URL" of about "T." news

news.google.com/rss/articles/CBMickFVX3lxTFBLbWxILU51QlJSQ2lLX3Q0ZDMyWHBjR05mcmlhbHk4em1CeHd3dnBkdkU0bXFjSHFER002WmNCSUVpTl9jQ1JGSFRGUEMzTDlvbHRjaDJ5ZWZ6ZGdScmZuc3pWeUZvOVFVazh6Z1AtSl9qdw?oc=5


Continue Opne >

T.: 藥華藥(6446)T細胞受體免疫療法TCRT-ESO-A2-TW用於治療末期實體 腫瘤患者之第一期臨床試驗申請案(IND)進度更新(1/2日股價602元)


More T. news:



Warning: filemtime(): stat failed for aCache/aaa/gnews/IE/T..xml in /var/www/hoodb/function.php on line 339
1736274441-
Warning: file_put_contents(aCache/aaa/gnews/IE//T..xml): Failed to open stream: No space left on device in /var/www/hoodb/function.php on line 348

About T.

from
1736274442-1735673249

Warning: filemtime(): stat failed for aCache/search/ie/T. in /var/www/hoodb/function.php on line 339
1736274442-

T., 藥華藥(6446)T細胞受體免疫療法TCRT-ESO-A2-TW用於治療末期實體 腫瘤患者之第一期臨床試驗申請案(IND)進度更新(1/2日股價602元) 2022 T.

藥華藥(6446)T細胞受體免疫療法TCRT-ESO-A2-TW用於治療末期實體 腫瘤患者之第一期臨床試驗申請案(IND)進度更新(1/2日股價602元)

Choose Your Country or Region


Back to Top



藥華藥(6446)T細胞受體免疫療法TCRT-ESO-A2-TW用於治療末期實體 腫瘤患者之第一期臨床試驗申請案(IND)進度更新(1/2日股價602元)

Copyright © 2020-2021 hoodb.com. All Rights Reserved.